The challenge of more robust and reproducible methodology in screening for primary aldosteronism
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Primary aldosteronism (PAL) is gaining recognition as an important cause of hypertension, and attention is focusing more critically on the reliability of screening tests for PAL. However, less attention has focused on reliable tests to establish a firm diagnosis, or on tests to differentiate the surgically correctable form, unilateral aldosterone-producing adenoma (APA), associated with a ‘normal’ contralateral adrenal, from other forms. In this issue of the journal, Ferrari et al. [1] make a small but significant contribution to these difficult but important questions by showing that immunoreactive renin (irR) can probably be substituted for the theoretically more variable (i.e. because of widely differing conditions of assay) plasma renin activity (PRA), which incorporates assessment of renin substrate (angiotensinogen), and which has contributed so much to our early understanding of renin–angiotensin–aldosterone physiology. More reproducible assays are essential at this critical time for the management of PAL because, due to the wide availability of commercial ‘kits', the measurement of aldosterone to renin ratio (ARR) has moved from the basic research or Specialized Unit laboratory, with meticulous quality control, clinical feedback and long experience, to the busy shrinking budget-driven general hospital laboratory and to the profit-driven private laboratory. Although clearly preferable, the smaller laboratories possibly could not cope with the heavy load of widely based screening. It might reasonably be expected that there is less laboratory to laboratory variability with irR (with an international standard for renin) than with PRA, permitting comparison and even pooling of results in patients from different clinical units. This might strengthen our combined ability to resolve some of the important issues regarding screening for PAL, together with its firm diagnosis and optimal treatment. By confining the question to a direct comparison of PRA and irR measured simultaneously in the same sample in order to determine ARR, Ferrari et al. [1] have effectively avoided becoming bogged down in the many other more complex, important, practical issues such as posture, time of day, methods for measuring plasma aldosterone concentration (PAC) and medications, although they briefly refer to some of them in their introduction and discussion, and of necessity, make their choice of sampling conditions for the study. Within that restricted context and despite the small number of patients involved (36 in all), their study delivers a relatively clear answer. Ideally, this should be confirmed in a larger study. As expected, there was an excellent correlation between irR and PRA values, although admittedly not quite as robust at the important lower end of the range, but hopefully the assay is accurate enough at these levels for meaningful discrimination. Because the same value for PAC was used in each case, there was also an excellent correlation between ARRs measured using these two techniques for estimating renin. Differences between what is actually measured by PRA and by irR are briefly discussed. The authors reasonably conclude that irR may be as useful as PRA to assay renin in clinical practice in screening for PAL. However, one could question how Table 1, which usefully converts the cut-off point for ARR from only one study [2] into the various units used by different authors (mass or SI units), takes into account the different methods used in the literature, as suggested by the authors.Table 1: Possibly useful guidelines for application of aldosterone to renin ratio (ARR) in screening for primary aldosteronismWhile the aldosterone level is in fact a less powerful determinant of ARR than renin, which seems to move physiologically on a logarithmic scale, nevertheless the radioimmunoassay of PAC using commercial kits is not free from problems, especially if the long-utilized antibody component is exhausted and replaced by another by the manufacturer, without adequate examination of the effects of this on the assay. The problem of reproducibility of the aldosterone assay, when performed in different laboratories, is not addressed by Ferrari et al. [1]; it would be very useful to have this information. Perhaps future approaches to the measurement of aldosterone which more directly estimate mass will help to resolve it. In the meantime, the same difficulties of comparison of results from different laboratories employing different kits remains for aldosterone as for renin. The wider and more general scientific problem which this study briefly addresses is the possibly unanswerable question of a precise cut-off point for ARR in screening for PAL. This question is of very great importance now that it is widely recognized that PAL is not uncommon among the hypertensive population, indeed it is common enough and specifically treatable enough to make failure to detect its presence a significant clinical oversight. Some of th
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lifton, R. P., Dluhy, R. G., Powers, M., Rich, G. M., Cook, S., Ulick, S., & Lalouel, J.-M. (1992) · Nature · doi:10.1038/355262a0 · Cited by 1,158
Cited by
Cardiovascular Outcomes in Patients With Primary Aldosteronism After Treatment
Catena, C. (2008) · Archives of Internal Medicine · doi:10.1001/archinternmed.2007.33 · Cited by 565
Käyser, S. C., Dekkers, T., Groenewoud, H. J., van der Wilt, G. J., Carel Bakx, J., van der Wel, M. C., Hermus, A. R., Lenders, J. W., & Deinum, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1472 · Cited by 398
Long-term Renal Outcomes in Patients With Primary Aldosteronism
Sechi, L. A., Novello, M., Lapenna, R., Baroselli, S., Nadalini, E., Colussi, G. L., & Catena, C. (2006) · JAMA · doi:10.1001/jama.295.22.2638 · Cited by 388
Mulatero, P., Monticone, S., Deinum, J., Amar, L., Prejbisz, A., Zennaro, M.-C., Beuschlein, F., Rossi, G. P., Nishikawa, T., Morganti, A., et al. (2020) · Journal of Hypertension · doi:10.1097/hjh.0000000000002510 · Cited by 317
Adrenal Vein Sampling: How to Make It Quick, Easy, and Successful
Daunt, N. (2005) · RadioGraphics · doi:10.1148/rg.25si055514 · Cited by 315
Metadata
- Authors
- Gordon, R. D.
- Venue
- Journal of Hypertension
- Published
- 2004-02
- Volume
- 22
- Issue
- 2
- Pages
- 251-255
- ISSN
- 0263-6352 (ISSN-L)
- OpenAlex
- W2086150337
- Cited by
- 70
- References
- 1
- FWCI
- 4.96
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The challenge of more robust and reproducible methodology in screening for primary aldosteronism. https://app.cochat.ai/papers/10.1097/00004872-200402000-00006
- The paper
- Gordon, R. D. (2004). The challenge of more robust and reproducible methodology in screening for primary aldosteronism. Journal of Hypertension. https://doi.org/10.1097/00004872-200402000-00006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.